Special Issue: One Health Drugs Against Vector-Borne Parasitic Diseases—a Sustainable Chemical/Biological Approach -molecule

Dear Colleagues,

Vector-borne parasitic diseases continue to pose a significant threat to human and animal health worldwide, especially in tropical and subtropical regions. This problem requires consolidation on intersectorial and multisectorial levels under One Health approach including public health, veterinary medicine and ecological/biological scientific and practical community. These diseases, including malaria, leishmaniasis, filariasis, and trypanosomiasis, and many others are intricately linked to ecological changes, animal reservoirs, and the complex dynamics of vector populations. In the context of the One Health framework—which recognizes the interconnectedness of human, animal, and environmental health—there is a pressing need for integrated, sustainable strategies to combat parasitic diseases, including development of new drugs against biological agents and their vectors, its potency, efficacy and safety considerations.

This special issue aims to bring together original research, reviews, and perspectives on the development of novel chemical and biological therapeutics targeting vector-borne parasitic pathogens. Contributions will explore innovative drug discovery pipelines, repurposing of existing compounds, bioactive natural products, and synthetic molecules with antiparasitic activity. We also highlight advances in host-targeted therapies, parasite resistance mechanisms, and integrated vector control strategies.

By uniting chemical biology, parasitology, pharmacology, and One Health sciences, this issue seeks to inspire collaborative, cross-sectoral solutions to mitigate the burden of parasitic diseases in an increasingly interconnected world

The main baselines of our issue would be:

1. One Health Framework against vector-borne parasitic diseases

• Integration of human, animal, and environmental health in parasitic disease control.
• Role of zoonotic cycles and animal reservoirs in disease persistence.
• Socio-ecological drivers of vector-borne parasitic diseases.

2. Chemical and Biological Therapeutic Discovery

• Screening of natural products, synthetic compounds, and marine/plant-derived agents.
• Drug repurposing and repositioning strategies.
• Development of multi-targeted or host-directed therapies.
• Novel delivery systems (e.g., nanocarriers, injectable depots).

3. Vector and Transmission Control